Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

17%(1 trials)

Phase Distribution

Ph phase_1

83%

Ph phase_2

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

5(83.3%)

Phase 2Efficacy & side effects

1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 15 (83.3%)

Phase 21 (16.7%)

Trials by Status

completed6100%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_2

Imexon for Relapsed Follicular and Aggressive Lymphomas

NCT01314014

completedphase_1

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

NCT00327288

completedphase_1

Clinical Trials (6)

Showing 6 of 6 trials

NCT01314014Phase 2

Imexon for Relapsed Follicular and Aggressive Lymphomas

Completed

NCT00327288Phase 1

Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients

Completed

NCT00327600Phase 1

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

Completed

NCT00327327Phase 1

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

Completed

NCT00327249Phase 1

Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

Completed

NCT00327223Phase 1

Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6